SCHEMBL29454091

SCHEMBL29454091

Cc1cc(N)c(Cl)c(Nc2ccc(C(C)(C)C)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
GAA P10253 5/20 0.39
TDP1 Q9NUW8 2/20 0.39
HSD17B2 P37059 3/20 0.39
SLC2A1 P11166 1/20 0.39
AKR1C3 P42330 2/20 0.38
AKR1C2 P52895 2/20 0.38
TSHR P16473 1/20 0.37
KDM4E B2RXH2 3/20 0.35
NPC1 O15118 3/20 0.35
GFER P55789 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 4/20 0.35
ALDH1A1 P00352 4/20 0.35
KMT2A Q03164 4/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
RAB9A P51151 2/20 0.35
RECQL P46063 2/20 0.35
POLB P06746 1/20 0.35
CASP6 P55212 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23908293 0.89 TSHR (0.43) MAPTGAAHSD17B2SLC2A1AKR1C3
SCHEMBL22060593 0.88 RAPGEF4 (0.44) HSD17B2SLC2A1AKR1C3AKR1C2TSHR
SCHEMBL22232177 0.85 GAA (0.53) MAPTGAATDP1AKR1C3AKR1C2
SCHEMBL29454181 0.85 GAA (0.53) MAPTGAATDP1AKR1C3AKR1C2
SCHEMBL22051005 0.84 SLC2A1 (0.40) MAPTHSD17B2SLC2A1AKR1C3AKR1C2
SCHEMBL22232474 0.84 NPC1 (0.44) MAPTGAATDP1SLC2A1AKR1C3
SCHEMBL29454186 0.84 NPC1 (0.44) MAPTGAATDP1SLC2A1AKR1C3
SCHEMBL22231721 0.81 BPTF (0.41) MAPTGAATDP1KDM4ENPC1
SCHEMBL29454349 0.81 BPTF (0.41) MAPTGAATDP1KDM4ENPC1
SCHEMBL23589605 0.81 SLC2A1 (0.42) GAAHSD17B2SLC2A1AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US claimed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US disclosed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP disclosed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS MAPT 3811/4885GAA 1080/4885TDP1 1133/4885
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof CBR1, CBR3, HCCS MAPT 4483/4885GAA 2001/4885TDP1 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.